FDA Drug recall D-0783-2026
Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 2…
- FDA Drug
- Class II
- ongoing
- Published 2026-09-02
On 2026-09-02 the FDA classified a Class II recall of Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 2… by Accord Healthcare, citing subpotent Drug.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0783-2026 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2026-08-06 |
| Published | 2026-09-02 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Accord Healthcare |
| Distribution | US |
Product
Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-455-17.
Reason
Subpotent Drug
Identifiers
| ndc | 16729-458-15 |
|---|---|
| ndc | 16729-458-17 |
| ndc | 16729-447-15 |
| ndc | 16729-447-17 |
| ndc | 16729-448-15 |
| ndc | 16729-448-17 |
| ndc | 16729-449-15 |
| ndc | 16729-449-17 |
| ndc | 16729-451-15 |
| ndc | 16729-451-17 |
| ndc | 16729-450-15 |
| ndc | 16729-450-17 |
| ndc | 16729-452-15 |
| ndc | 16729-452-17 |
| ndc | 16729-453-15 |
| ndc | 16729-453-17 |
| ndc | 16729-454-15 |
| ndc | 16729-454-17 |
| ndc | 16729-455-15 |
| ndc | 16729-455-17 |
| ndc | 16729-456-15 |
| ndc | 16729-456-17 |
| ndc | 16729-457-15 |
| ndc | 16729-457-17 |
| code_info | Lot #: D2402195, D2402196, D2402197, Exp. Date 09/30/2026. |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0783-2026%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.